Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).
“People are scared to discuss these things,” Nelson said. “However, seeking medical advice is crucial for proper diagnosis ...
The latest data from WHO show that tuberculosis remains a formidable global health concern, with an estimated 10·8 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback